Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768751 | 0.81 | CFTR (0.33) | LTC4SCFTR | |
| SCHEMBL2767334 | 0.76 | LTC4S (0.35) | LTC4S | |
| SCHEMBL2768179 | 0.76 | — | — | |
| SCHEMBL2768177 | 0.76 | — | — | |
| SCHEMBL5078801 | 0.75 | — | — | |
| SCHEMBL3641662 | 0.72 | TBK1 (0.34) | CFTR | |
| SCHEMBL20483929 | 0.68 | ALDH1A1 (0.32) | — | |
| SCHEMBL14909257 | 0.66 | PIK3CA (0.35) | — | |
| SCHEMBL18284436 | 0.64 | PTGFR (0.32) | — | |
| SCHEMBL14909691 | 0.64 | SLC13A5 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | BALLELL-PAGES LLUIS | 2010-07-22 | — | — | US | disclosed |
| US-7732460-B2 | Heterocyclic compounds, their preparation and their use as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-20100137353-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| EP-1963324-B1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2010-04-21 | — | — | EP | disclosed |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| EP-2005995-A1 | Heterocyclic compounds for the treatment of tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | EP | disclosed |
| EP-1963324-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2008-09-03 | — | — | EP | disclosed |
| US-20070185153-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| WO-2007071936-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185153-A1 | COMPOUNDS | NRDC, NISCH, MRPL21 | LTC4S 599/4885CFTR 946/4885 |
| US-20100137353-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | NRDC, NACA, NOP2 | LTC4S 1034/4885CFTR 1344/4885 |
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | SDHA, SDHB, NNT | LTC4S 129/4885CFTR 371/4885 |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | MRPL21, NACA, NISCH | LTC4S 1091/4885CFTR 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.